What sections make up a peptide certificate of analysis?
A well-constructed COA is modular, and understanding each block makes interpretation straightforward. The identity header lists the sequence (one-letter or three-letter code), molecular formula, theoretical average and monoisotopic mass, and any modifications such as amidation, acetylation or disulfide bridging that shift the expected mass. The appearance and physical description block records the lyophilised form and colour. The purity section reports the HPLC method, column chemistry, mobile-phase gradient and the main-peak area percent. The identity-confirmation section presents the mass spectrometry result — typically the observed [M+H]+ or multiply-charged envelope from ESI, or the singly protonated ion from MALDI. Supporting sections may include water content (Karl Fischer), counter-ion or residual-solvent data, and net peptide content where amino acid analysis has been performed. Finally, a metadata block records batch/lot number, manufacture and analysis dates, analyst and instrument identifiers, and reference to the governing specification. When interpreting a report, first confirm that the stated sequence and theoretical mass on the header are self-consistent, because every downstream number is judged against those values. A COA that omits the analytical conditions — column, gradient, ionisation mode, instrument — is far harder to evaluate, because purity and mass figures are only meaningful in the context of the method that produced them. For a research peptide, the COA should be filed as a traceable record tied to the physical vial, so that any later re-analysis can be compared against the original data. Certified reference material workflows illustrate the rigour possible when identity and content are anchored to orthogonal, quantitative methods (Feng L et al, 2020).
How do you read the HPLC purity result on a COA?
The HPLC section is usually the headline number on a peptide analysis report, and it is almost always reported as area-percent purity of the main peak in a reversed-phase (RP-HPLC) chromatogram. Interpretation begins with the method conditions: a C18 column, a water/acetonitrile gradient with an acidic modifier such as trifluoroacetic acid, a defined flow rate, column temperature and UV detection wavelength (commonly 214 nm for the peptide bond or 220 nm). Purity is calculated by dividing the target peak area by the total integrated peak area, excluding the injection front and solvent peaks. Two chromatograms are more informative than one number: the profile shows whether impurities elute close to the main peak (structurally similar related substances such as deletion or oxidation products) or far from it. A single sharp, symmetrical peak with a stable, well-characterised retention time indicates a clean separation, whereas shoulders, fronting or tailing may signal co-eluting species that inflate the apparent purity. This is why a COA should state that peak purity was assessed — ideally with a diode-array (PDA) spectral homogeneity check across the peak, or with an orthogonal gradient. When reading the report, note the wavelength, because chromophore-poor peptides give weak UV signals and integration thresholds then matter more. Historically, coupling separation directly to mass detection greatly improved confidence that a chromatographic peak corresponds to a single species, as demonstrated in early on-line HPLC–MS analyses of enzymatic digests (Mock K et al, 1989). Treat the reported purity as method-dependent: the same batch analysed on a different column or gradient may return a slightly different figure, so record the exact conditions alongside the result.
How is peptide identity confirmed by mass spectrometry?
Mass spectrometry is the identity backbone of a peptide COA. The report should list an observed mass and the theoretical mass, and the two should agree within the stated tolerance of the instrument. Electrospray ionisation (ESI) typically produces a series of multiply-charged ions; deconvolution of that charge envelope yields a neutral molecular weight that is compared to the calculated average mass. MALDI generally produces predominantly singly charged ions, and its spectra are often read against the monoisotopic or average mass depending on resolution. Matrix selection influences MALDI signal quality, and ongoing method development continues to refine matrices for peptide analysis (Yamaguchi M et al, 2025). When interpreting the MS section, check three things: which ionisation mode and mass type (monoisotopic versus average) the value represents, whether the mass difference between observed and theoretical is within a few tenths of a dalton for high-resolution data, and whether any satellite peaks correspond to predictable adducts (sodium, potassium) or modifications (oxidation adds ~16 Da; loss of water subtracts ~18 Da). A mass matching the theoretical value confirms molecular weight but not sequence; conversely, an unexpected mass flags a synthesis or handling issue that HPLC purity alone would not reveal. Complex mixtures and multidimensional spectra benefit from automated reduction and interpretation routines that assign peaks systematically (Gambin A et al, 2007). Historic sequence-analysis work using secondary ion mass spectrometry established the principle that molecular mass measurement can anchor identity for an unknown peptide (Seki S et al, 1985).
What does tandem MS (MS/MS) add to sequence verification?
Where the intact-mass measurement confirms molecular weight, tandem mass spectrometry (MS/MS) confirms sequence by fragmenting a selected precursor ion and reading the resulting product ions. In a COA context, an MS/MS section provides the strongest available identity evidence because it distinguishes isobaric peptides — sequences that share the same intact mass but differ in residue order or in the position of a modification. Interpretation relies on the b- and y-ion series: consecutive fragment masses differ by the residue mass of each amino acid, and mapping those differences reconstructs the sequence. When reading such data, confirm that the reported fragment table matches the claimed sequence and that coverage spans the peptide rather than only its termini. Tandem MS has long been applied to characterise synthetic peptide analogues, distinguishing closely related structures that intact mass alone cannot resolve (Tseng J-L et al, 1995). Capillary electrophoresis coupled to MS and MS/MS similarly demonstrated confident characterisation of standard peptide mixtures (Major HJ et al, 1996). Advanced fragmentation and cross-linking chemistries, including free radical–initiated peptide sequencing approaches, continue to expand the structural detail obtainable from a single experiment (Iacobucci C et al, 2019). For most research peptide COAs, an intact-mass plus a purity figure is standard; an MS/MS or sequence-verification report is a higher tier of documentation worth requesting when isobaric impurities, modified residues or unusual analogues are involved. Always cross-reference the MS/MS assignment against the header sequence — the fragment ladder should be reproducible from the stated residues.
How do you cross-check purity, mass and content for internal consistency?
A robust interpretation treats the COA as a set of results that must agree with one another. HPLC area-percent purity, the MS-confirmed identity and any quantitative content figure describe different properties, and reconciling them is where analytical judgement matters. Chromatographic purity is a relative measure — the fraction of UV-absorbing material attributable to the main peak — and does not, on its own, tell you how much peptide is present by mass. Net peptide content is a separate determination, classically established through amino acid analysis or isotope-dilution quantification, which accounts for water, counter-ions and residual solvents that add to the gross powder weight. The certification of amyloid-beta reference materials illustrates how orthogonal quantitative methods, including amino acid–based isotope dilution HPLC-MS, are combined to assign content with defined uncertainty (Feng L et al, 2020). When interpreting a report, ask whether a high HPLC purity is accompanied by a content or water-content figure; a 98 percent pure peptide can still be well under 98 percent peptide by mass because of bound water and salts. Check that the mass spectrometry result corresponds to the same species that dominates the chromatogram — ideally the report links the two by analysing the collected main peak. Confirm that dates are logical (analysis after manufacture), that the lot number matches the vial label, and that the method references are complete enough to permit re-analysis. Document any discrepancies, retain the COA with the batch record, and where independent verification is required, plan confirmatory HPLC and intact-mass checks in your own laboratory against the same acceptance criteria.
Frequently asked questions
What is the difference between HPLC purity and peptide content on a COA?
HPLC purity is a relative area-percent measure of how much of the UV-absorbing signal comes from the main peak. Peptide content is an absolute quantitative measure of how much peptide is present by mass, determined separately (for example by amino acid analysis), and accounts for water, counter-ions and residual solvents in the powder.
Why do the observed and theoretical masses on a COA differ slightly?
Small differences reflect whether the value is monoisotopic or average mass, the resolution of the instrument, and the ionisation mode. Larger unexpected shifts may indicate adducts such as sodium, or modifications such as oxidation (about +16 Da) or water loss (about -18 Da), which should be flagged during interpretation.
Does a matching molecular weight confirm the peptide sequence?
No. A matching intact mass confirms molecular weight but not residue order. Isobaric peptides share the same mass yet differ in sequence. Tandem mass spectrometry (MS/MS) fragmentation and the resulting b/y-ion ladder are required to verify the actual sequence against the claimed structure.
What analytical conditions should a peptide COA state for HPLC?
A complete COA lists the column chemistry (commonly C18), the mobile-phase gradient and modifier, flow rate, column temperature, detection wavelength (often 214 or 220 nm) and the integration approach. Purity figures are method-dependent, so these conditions are essential for meaningful interpretation and any later re-analysis.
Should peak purity be checked beyond the reported percentage?
Yes. Ideally a diode-array spectral homogeneity check or an orthogonal gradient confirms that a single peak is not hiding co-eluting species. Coupling separation directly to mass detection also increases confidence that a chromatographic peak corresponds to one molecular species rather than several.
References
- PMID:32847351 — Certification of Amyloid-Beta (Aβ) Certified Reference Materials by Amino Acid-Based Isotope Dilution High-Performance Liquid Chromatography Mass Spectrometry and Sulfur-Based High-Performance Liquid Chromatography Isotope Dilution Inductively Coupled Plasma Mass Spectrometry — Anal Chem — 2020
- DOI:10.1002/oms.1210240813 — Application of on‐line HPLC‐FAB mass spectrometry to the analysis of enzymatic digests of ribonuclease B — Organic Mass Spectrometry — 1989
- DOI:10.5702/massspectrometry.a0170 — Alkylated Hydroxychalcone: A Novel Matrix for Peptide Analysis by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry — Mass Spectrometry — 2025
- DOI:10.1016/j.ijms.2006.06.011 — Automated reduction and interpretation of multidimensional mass spectra for analysis of complex peptide mixtures — International Journal of Mass Spectrometry — 2007
- DOI:10.1002/oms.1210200107 — Sequence analysis for an unknown peptide by molecular secondary ion mass spectrometry — Organic Mass Spectrometry — 1985
- DOI:10.1002/rcm.1290090404 — Tandem mass spectrometry analysis of synthetic opioid peptide analogs — Rapid Communications in Mass Spectrometry — 1995
- DOI:10.1002/(sici)1097-0231(199608)10:11<1421::aid-rcm651>3.3.co;2-4 — Analysis of a Standard Peptide Mixture by Capillary Electrophoresis with Mass Spectrometry and with Tandem Mass Spectrometry — Rapid Communications in Mass Spectrometry — 1996
- DOI:10.1002/mas.21568 — Free radical‐initiated peptide sequencing (FRIPS)‐based cross‐linkers for improved peptide and protein structure analysis — Mass Spectrometry Reviews — 2019
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
